Table 1

Patient characteristics and GORD impact scale for the three subgroups of participation: attended the Cytosponge appointment and completed the baseline questionnaire (‘attenders’); completed the follow-up questionnaire (‘follow-up responders’) or Interviewed (‘interviewees’)

Completed baseline questionnaire (‘attenders’)
(N=1750)
Completed follow-up questionnaire (‘follow-up responders’)
(N=1488)
Interviewed (‘interviewees’)
(N=30)
P values for χ2 test between ‘follow-up responders’ (N=1488) and ‘attenders’ who are not ‘follow-up responders’ (N=262)
N%N%N%
Sex
 Female919537825215500.985
 Male83047706471550
 Missing1<10000
Age group
 50–5934520285194130.028*
 60–6959634497331135
 70–796473757238929
 80–9916191349619
 Missing1<10013
Cytosponge-TFF3 outcome (after repeat test)
 TFF3 negative12527211267614470.246†
 TFF3 positive23113213141033
 Inadequate (equivocal/low-confidence negative/technical or processing failure)171101491027
 Unsuccessful swallow96500413
Underwent repeat Cytosponge test
 No15608913228925830.338
 Yes1901116611517
Education level
 School up to 15–16 years of age712416054116530.104
 College or vocational school5373145531827
 Professional training beyond college, university graduate or postgraduate degree4802741428413
 Other or prefer not to say21114127
Waist-hip ratio
 <0.90685396014011370.010*
 0.90<0.9968639562381033
 0.99+3782232422930
 Missing1<11<100
Comorbidities
 No22813182126200.018*
 Yes1522871306882480
Medication duration
 Less than 5 years51830431297230.166
 More than 5 years1232701057712377
 Diagnoses
 No Barrett’s oesophagus16189213679226870.118
 Barrett’s oesophagus—without dysplasia11771067413
 Barrett’s oesophagus—with dysplasia11111100
 Oesophageal adenocarcinoma (stage 1)4<14<100
P values for t-test between‘follow-up responders’ (N=1488) and ‘attenders’ who are not ‘follow-up responders’ (N=262)
GORD Impact Scale—before taking acid-suppressant medications
 Mean (SD)1.9 (0.5)1.9 (0.5)1.9 (0.5)0.319
 No. missing210
GORD Impact Scale—In the last week
 Mean (SD)1.3 (0.4)1.3 (0.4)1.3 (0.5)0.451
 No missing000
  • *P<0.05.

  • †Comparison excluding participants producing an unsuccessful swallow as they were not invited to fill in a follow-up questionnaire.

  • GORD, gastro-oesophageal reflux disease ; TFF3, trefoil factor 3.